Basilea Pharmaceutica (BPMUF) News Today $52.83 0.00 (0.00%) As of 01/17/2025 Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Short Interest in Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Drops By 34.4%Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) was the target of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 16,400 shares, a drop of 34.4% from the December 15th total of 25,000 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.January 15, 2025 | marketbeat.comBasilea provides portfolio update and outlookJanuary 8, 2025 | finance.yahoo.comBasilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest UpdateBasilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totalling 25,000 shares, a drop of 11.0% from the November 30th total of 28,100 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.December 30, 2024 | marketbeat.comKepler Capital Sticks to Their Buy Rating for Basilea Pharmaceutica (BSLN)December 21, 2024 | markets.businessinsider.comKepler Capital Keeps Their Buy Rating on Basilea Pharmaceutica (BSLN)December 18, 2024 | markets.businessinsider.comInnoviva enters distribution, license agreement with Basilea for ZevteraDecember 17, 2024 | markets.businessinsider.comBasilea Pharmaceutica AG (BSLN.SW)November 10, 2024 | finance.yahoo.comBasilea Pharmaceutica (OTCMKTS:BPMUF) Hits New 12-Month High - What's Next?Basilea Pharmaceutica (OTCMKTS:BPMUF) Hits New 12-Month High - Here's WhyOctober 24, 2024 | marketbeat.comStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this yearOctober 10, 2024 | markets.businessinsider.comBasilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasisSeptember 24, 2024 | markets.businessinsider.comBasilea Pharmaceutica (BSLN) Gets a Buy from Kepler CapitalSeptember 22, 2024 | markets.businessinsider.comBasilea Reaches Deal With BARDA To Develop Novel Antifungals And Antibacterials; Raises FY OutlookSeptember 19, 2024 | markets.businessinsider.comStrong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to BasileaSeptember 6, 2024 | markets.businessinsider.comBasilea Receives $25 Mln Milestone Payment Following Strong Cresemba Sales Performance In EuropeSeptember 6, 2024 | markets.businessinsider.comHC Wainwright Weighs in on Basilea Pharmaceutica AG's FY2024 Earnings (OTCMKTS:BPMUF)Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Free Report) - Stock analysts at HC Wainwright lifted their FY2024 earnings per share estimates for shares of Basilea Pharmaceutica in a research report issued to clients and investors on Wednesday, August 28th. HC Wainwright analyst R. Selvaraju now expeAugust 30, 2024 | marketbeat.comBasilea Pharmaceutica AG (BPMUF)August 29, 2024 | finance.yahoo.comShort Interest in Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Declines By 57.0%Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) was the recipient of a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 31,100 shares, a decline of 57.0% from the July 31st total of 72,300 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days.August 28, 2024 | marketbeat.comHalf Year 2024 Basilea Pharmaceutica AG Allschwil Earnings Call TranscriptAugust 16, 2024 | gurufocus.comBasilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidanceAugust 13, 2024 | markets.businessinsider.comBasilea Pharma H1 Results Down; Lifts FY24 GuidanceAugust 13, 2024 | markets.businessinsider.comBasilea Pharmaceutica (BSLN) Receives a Buy from Kepler CapitalAugust 3, 2024 | markets.businessinsider.comStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaMay 16, 2024 | finance.yahoo.comBPMUF Basilea Pharmaceutica AGMay 4, 2024 | seekingalpha.comBasilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024May 3, 2024 | finance.yahoo.comBasilea shareholders approve all proposals of the board of directors at the annual general meetingApril 24, 2024 | finance.yahoo.comBasilea Pharmaceutica AG (0QNA.L)April 24, 2024 | finance.yahoo.comBasilea awarded CARB-X grant to develop recently acquired novel class of antibioticsApril 9, 2024 | finance.yahoo.comUPDATE 2-US FDA approves Basilea Pharmaceutica's antibioticApril 4, 2024 | msn.comEuropean stocks rise ahead of inflation data; Basilea shinesApril 4, 2024 | msn.comBasilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicationsApril 4, 2024 | finance.yahoo.comUS FDA approves Basilea Pharmaceutica's antibioticApril 3, 2024 | reuters.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaMarch 11, 2024 | finance.yahoo.comBasilea Pharmaceutica AG Expected to Earn FY2024 Earnings of $1.85 Per Share (OTCMKTS:BPMUF)Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Free Report) - Equities research analysts at Edison Inv. Res dropped their FY2024 earnings per share estimates for Basilea Pharmaceutica in a research report issued on Tuesday, February 20th. Edison Inv. Res analyst S. Romanoff now anticipates that the coFebruary 22, 2024 | marketbeat.comBasilea Pharmaceutica AG (BSLN)February 21, 2024 | investing.comBasilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolioFebruary 13, 2024 | finance.yahoo.comCresemba® sales in Latin America trigger first sales milestone payment to BasileaJanuary 19, 2024 | finance.yahoo.comBasilea To Buy Preclinical Antibiotics Program From SpexisJanuary 15, 2024 | markets.businessinsider.comBasilea announces acquisition of preclinical antibiotics program from SpexisJanuary 15, 2024 | finance.yahoo.comBasilea provides portfolio status updateJanuary 5, 2024 | finance.yahoo.comBasilea Pharmaceutica Agrees With Athyrium On Early Repayment Of Senior Secured LoanDecember 20, 2023 | markets.businessinsider.comBasilea announces accelerated loan repaymentDecember 20, 2023 | finance.yahoo.comBasilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosisDecember 11, 2023 | finance.yahoo.comBasilea Pharmaceutica AG's (VTX:BSLN) top owners are individual investors with 58% stake, while 39% is held by institutionsDecember 4, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this yearNovember 20, 2023 | finance.yahoo.comPfizer unit in pact with Swiss biotech Basilea to sell rights to antifungalNovember 13, 2023 | msn.comBasilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungalNovember 13, 2023 | finance.yahoo.comBasilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agentOctober 31, 2023 | finance.yahoo.comBasilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infectionsOctober 19, 2023 | finance.yahoo.comBasilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023October 17, 2023 | finance.yahoo.comBasilea announces FDA acceptance of New Drug Application for antibiotic ceftobiproleOctober 2, 2023 | finance.yahoo.com Get Basilea Pharmaceutica News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMUF and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMUF Media Mentions By Week BPMUF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BPMUF News Sentiment▼1.860.63▲Average Medical News Sentiment BPMUF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BPMUF Articles This Week▼10▲BPMUF Articles Average Week Get Basilea Pharmaceutica News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMUF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RXRX News Today AMRX News Today SWTX News Today JANX News Today ARWR News Today VERA News Today NAMS News Today PTGX News Today CGON News Today MIRM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:BPMUF) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Basilea Pharmaceutica AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Basilea Pharmaceutica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
